MTST (MetaStat) FCF Yield %: 0.00 (As of Jun. 27, 2026)


What is MetaStat FCF Yield %?

MetaStat MTST FCF Yield % is 0.00 as of Jun. 27, 2026.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, MetaStat's Trailing 12-Month Free Cash Flow is $-2.74 Mil, and Market Cap is $0.01 Mil. Therefore, MetaStat's FCF Yield % for today is 0.00%.

The historical rank and industry rank for MetaStat's FCF Yield % or its related term are showing as below:


MTST's FCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -9.715
* Ranked among companies with meaningful FCF Yield % only.

MetaStat's FCF Margin % for the quarter that ended in Feb. 2018 was 0.00%.

MetaStat FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

MetaStat FCF Yield % Related Terms

MetaStat FCF Yield % Historical Data

* Premium members only.

The historical data trend for MetaStat's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat FCF Yield % Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.15 -18.99 -98.84 -32.97 -38.37

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.81 -45.58 -64.63 -101.74 -25.62

MTST vs OBMP, NSPX, ATRX: FCF Yield % Comparison

For the Biotechnology subindustry, MetaStat's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's FCF Yield % distribution charts can be found below:

* The bar in red indicates where MetaStat's FCF Yield % falls into.


MetaStat FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

MetaStat's FCF Yield % for the fiscal year that ended in Feb. 2018 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-2.774 / 7.22871
=-38.37%

MetaStat's annualized FCF Yield % for the quarter that ended in Feb. 2018 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.463 * 4 / 7.22871
=-25.62%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of 0.00 mean?
MetaStat (MTST) has a FCF Yield % of 0.00 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MetaStat and its competitors.
Is MetaStat's FCF Yield % too high?
MetaStat's current FCF Yield % is 0.00.
How does MetaStat's FCF Yield % compare to OBMP and NSPX?
MetaStat's FCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MetaStat and its competitors. MetaStat's current FCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current FCF Yield % of 0.00. The current FCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For MetaStat (MTST), the current FCF Yield % is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.